Physician profile
Michael Collins
NPI 1619069648
$4,671.72
in general payments reported to CMS, 2019-2025
13 companies · $3,847 in 2025
The $3,847 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.28 · 2024: $814 · 2025: $3,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,588.95 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,023.32 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $698.61 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $595.43 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $355.74 | 2025 | Cobenfy |
| Indivior INC. | $347.04 | 2024-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $320.45 | 2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $307.94 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $295.98 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $248.43 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $191.05 | 2021-2025 | |
| Braeburn INC. | $147.66 | 2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.79 | 2025 | Caplyta |
| Lundbeck LLC | $68.28 | 2024-2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.